Duan, D., Yue, Y. & Engelhardt, J.F. in Lung Biology in Health and Disease, Gene Therapy in Lung Disease (ed. Albelda, S.M.) 51–92 (Marcel Dekker Inc., New York, NY, 2002).
Kay, M.A. et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24, 257–261 (2000).
Carter, B.J. Adeno-associated virus vectors in clinical trials. Hum. Gene Ther. 16, 541–550 (2005).
Dong, J.Y., Fan, P.D. & Frizzell, R.A. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 7, 2101–2112 (1996).
Duan, D. et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long term episomal persistence in muscle. J. Virol. 72, 8568–8577 (1998).
Duan, D., Yan, Z., Yue, Y. & Engelhardt, J.F. Structural analysis of adeno-associated virus transduction intermediates. Virology 261, 8–14 (1999).
Yue, Y. & Duan, D. Double strand interaction is the predominant pathway for intermolecular recombination of adeno-associated viral genomes. Virology 313, 1–7 (2003).
Yan, Z., Zhang, Y., Duan, D. & Engelhardt, J.F. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc. Natl. Acad. Sci. USA 97, 6716–6721 (2000).
Sun, L., Li, J. & Xiao, X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat. Med. 6, 599–602 (2000).
Nakai, H., Storm, T.A. & Kay, M.A. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat. Biotechnol. [see comments] 18, 527–532 (2000).
Duan, D., Yue, Y. & Engelhardt, J.F. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol. Ther. 4, 383–391 (2001).
Chao, H., Sun, L., Bruce, A., Xiao, X. & Walsh, C.E. Expression of human factor VIII by splicing between dimerized AAV vectors. Mol. Ther. 5, 716–722 (2002).
Reich, S.J. et al. Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. Hum. Gene Ther. 14, 37–44 (2003).
Yan, Z., Zak, R., Zhang, Y. & Engelhardt, J.F. Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J. Virol. 79, 364–379 (2005).
Xu, Z. et al. Trans-splicing adeno-associated viral vector-mediated gene therapy is limited by the accumulation of spliced mRNA but not by dual vector coinfection efficiency. Hum. Gene Ther. 15, 896–905 (2004).
England, S.B. et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180–182 (1990).
Harper, S.Q. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253–261 (2002).
Sironi, M. et al. Analysis of splicing parameters in the dystrophin gene: relevance for physiological and pathogenetic splicing mechanisms. Hum. Genet. 109, 73–84 (2001).
Chao, D.S. et al. Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J. Exp. Med. 184, 609–618 (1996).
Cartegni, L., Chew, S.L. & Krainer, A.R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 3, 285–298 (2002).
Ibrahimel, C., Schaal, T.D., Hertel, K.J., Reed, R. & Maniatis, T. Serine/arginine-rich protein-dependent suppression of exon skipping by exonic splicing enhancers. Proc. Natl. Acad. Sci. USA 102, 5002–5007 (2005).
Li, X. & Manley, J.L. Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell 122, 365–378 (2005).
Halbert, C.L., Allen, J.M. & Miller, A.D. Adeno-associated virus type 6 (aav6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of aav2 vectors. J. Virol. 75, 6615–6624 (2001).
Duan, D., Yue, Y., Yan, Z. & Engelhardt, J.F. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat. Med. 6, 595–598 (2000).
Liu, M. et al. Adeno-associated virus-mediated micro-dystrophin expression protects young mdx muscle from contraction-induced injury. Mol. Ther. 11, 245–256 (2005).
Yue, Y. et al. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 108, 1626–1632 (2003).
Yue, Y., Skimming, J.W., Liu, M., Strawn, T. & Duan, D. Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice. Hum. Mol. Genet. 13, 1669–1675 (2004).
Ervasti, J.M. & Campbell, K.P. Membrane organization of the dystrophin-glycoprotein complex. Cell 66, 1121–1131 (1991).